In July, Cepheid revised its forecast for 2008 sales from $182-$189 million to $173-$177 million, with product sales expected to be $164-$167 million, due to lower-than-expected noncore clinical partner purchases from BD and Roche and lower Biothreat sales due to a reduction in tests used by the US Postal Service

Instrument Business Outlook, August 31, 2008

In July, Cepheid revised its forecast for 2008 sales from $182-$189 million (see IBO 4/30/80) to $173-$177 million, with product sales expected to be $164-$167 million, due to lower-than-expected noncore clinical partner purchases from BD and Roche and lower Biothreat sales due to a reduction in tests used by the US Postal Service.

As of June 30, the company had an installed base of 717 GeneXpert systems and 3,560 modules.